Trenton, December 11, 2023 ― Chris Lepore, Chair of the Board of Trustees of the HealthCare Institute of New Jersey (HINJ) and Vice President, U.S. State Affairs, Johnson & Johnson, released the following statement announcing the retirement of HINJ President and Chief Executive Officer Dean J. Paranicas:
“After nearly 13 impactful years as President and Chief Executive Officer of the HealthCare Institute of New Jersey (HINJ), Dean Paranicas has announced his intention to retire, effective March 1, 2024. Over his long and successful tenure at HINJ, Dean has been a prominent and powerful advocate and voice for New Jersey’s life sciences community, patient access and strengthening our state’s world-class innovation ecosystem during particularly challenging times for the industry and global health. His steady stewardship of an effective and well-respected organization enabled HINJ to adapt and respond to new and ever-changing public policy environments on both the federal and state levels. Dean has built an enduring legacy at HINJ in New Jersey, Washington, DC and nationally.”
Paranicas stated, “It has been my distinct honor and privilege to have been a part of an industry for over 40 years with such a noble calling – to improve the human condition. New Jersey’s life sciences community is a pillar not only of our state’s workforce and economy, but also of global human health. I’m proud of HINJ’s many achievements during my tenure, and I am grateful for the opportunity to have worked on them so closely with many of the state’s thought leaders and policymakers in state and federal government, academia, industry, the national life sciences community, and, most importantly, the patient community, who are the ultimate beneficiaries of our industry’s work.”
Lepore continued, “HINJ will be conducting a thorough and comprehensive search process to identify the most qualified candidate to succeed Dean in leading the organization’s critically important work of protecting patient access while preserving the innovation ecosystem that works to discover new treatments and cures for the world’s most dreaded conditions. We are indebted to Dean for his years of inspired and energetic leadership and look forward to continuing HINJ’s legacy of strong and effective advocacy under his successor.”